Nano Group Ferro Group Stenting Control ANOVA, p value
Number of enrolled patients, no. 60 60 60 NA
Event-free survival (all cause), no. (%) 55 (91.7%) 49 (81.7%) 48 (80.0%) 0.031*
0.068
Target lesion cardiac death, no. (%) 0 (0%) 0 (0%) 1 (1.7%) > 0.05
Target vessel cardiac death, no (%) 0 (0%) 2 (3.3%) 1 (1.7%) 0.091
Non-cardiac death, no. (%):
• Stroke
• Trauma
• Cancer
• Others
5 (8.3%)
2 (3.3%)
2 (3.3%)
1 (1.7%)
0 (0%)
9 (15.0%)
3 (5.0%)
4 (6.7%)
1 (1.7%)
1 (1.7%)
10 (16.7%)
5 (8.3%)
4 (6.7%)
1 (1.7%)
0 (0%)
0.032*, 0.064
> 0.05
> 0.05
>0.05
>0.05
Target lesion myocardial infarction, no. (%) 0 (0%) 0 (0%) 2 (3.3%) > 0.05
Target vessel myocardial infarction, no. (%) 3 (5.0%) 6 (10.0%) 4 (6.7%) 0.029*, 0.059
Target lesion revascularization (TLR), no. (%) 2 (3.3%) 2 (3.3%) 4 (6.7%) 0.058, 0.039#
Target vessel revascularization (TVR), no. (%) 6 (10.0%) 12 (20.0%) 8 (13.3%) 0.061, 0.043#
Thrombosis of culprit artery, no. (%)
• ARC definite thrombosis
0 (0%)
0 (0%)
1 (1.7%)
1 (1.7%)
4 (6.7%)
4 (6.7%)
0.074, 0.028#
0.074, 0.028#
Newcomers with diabetes mellitus, no. (%)
• Insulin-dependent
9 (15.0%)
2 (3.3%)
8 (13.3%)
1 (1.7%)
5 (8.3%)
3 (5.0%)
0.058
> 0.05
Newcomers with SYNTAX score ≥23, no. (%) 4 (6.7%) 8 (10.0%) 7 (11.7%) 0.042*, 0.071
* - p-value for the difference between Nano and Ferro groups;
# - p-value for the difference between Nano and Control groups;
NA – non-available, or not applicable. Continuous variables are expressed as mean ± SD. ARC –Academic Research Consortium. The definition of definite on-site thrombosis was tailored to the type of intervention
Table 3: Clinical follow-up (one event per patient) at 12 months after the intervention (intention-to-treat analysis).